This site is best viewed with JavaScript enabled.

AlloMap®  The Future IMAGE of Heart Transplant Management

AlloMap is the only non-invasive gene expression test that helps physicians identify the absence* of heart transplant rejection

  • Provides Actionable Information: Quantifiable, objective, and reproducible test results
  • Offers Patient Comfort: Only requires a simple blood draw
  • Widely Adopted: Used 55,000 times in 105 of the approximately 126 heart transplant centers in the United States

*Absence is defined here as the very low probability of moderate/severe acute cellular rejection as measured by the negative predictive value. AlloMap test results are only to be used in conjunction with standard clinical assessment.

AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. Indicated for use in patients: 15 years of age or older and at least 2 months (≥ 55 days) since transplantation.

Patients share their experiences

patient_stories_Anne_01-260x134

Anne's Story

read more
patient_stories_BillW_02-260x134

Bill's Story

read more
patient_stories_Jack_03-260x134

Jack's Story

read more
patient_stories_Sally_04-260x134

Sally's Story

read more